ASCEND
2014
Pirfenidone in Idiopathic Pulmonary Fibrosis
In 555 patients with IPF (FVC 50–90% predicted), pirfenidone 2,403 mg/day reduced ≥10% FVC decline or death at 52 weeks compared with placebo.
Result
- Absolute difference
- 15.3 points
relative reduction47.9
The absolute difference is derived from the event rates.
Also reported: Pooled with CAPACITY, all-cause mortality HR 0.52.
- Subtopic
- Antifibrotic: IPF
- Design
- Multicentre RCT
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Cited in
- ATS/ERS 2015 IPF
- Source
- King TE Jr, et al. N Engl J Med. 2014;370(22):2083-2092.doi 10.1056/NEJMoa1402582
Discussion & critique
Together with CAPACITY, supported FDA approval of pirfenidone.